Drug intelligence / Profile preview

ADCMVTK

Development stage
Preclinical
Lead developer
Universidad de Navarra
Modality
Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration
Intra-arterial, Intraperitoneal, Intratumoral, Intravenous
01

Overview

**AdCMVtk** is a nonproprietary, replication-defective recombinant adenoviral gene-transfer vector designating constructs that express the **herpes simplex virus thymidine kinase** suicide gene under control of the cytomegalovirus promoter. Following transduction, HSV thymidine kinase phosphorylates subsequently administered ganciclovir, producing toxic nucleotide metabolites that inhibit DNA synthesis and cause death of transduced tumor cells, with potential bystander killing of neighboring cells. It has been used as an experimental preclinical gene-therapy tool in hepatocellular carcinoma and other tumor models, including in combination studies with adenoviral IL-12 vectors. The label does not define one uniquely standardized commercial product, adenoviral backbone, serotype, or manufacturing lot.

Other names
Ad-CMVtkAdCMVtkadenoviral cytomegalovirus-thymidine kinase vector
02

Targets

NeuraminidaseCXADR (Coxsackievirus and adenovirus receptor)

Beyond the preview

Go deeper on ADCMVTK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADCMVTK.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call